Topline results were announced from the phase 3 NODE-301 trial of etripamil nasal spray (Milestone Pharmaceuticals), a novel short-acting calcium channel blocker, being investigated for the at-home treatment of acute paroxysmal supraventricular tachycardia (PSVT).
A structural abnormality on cardiac magnetic resonance imaging may be a predictor of major adverse cardiac events in patients with nonsustained ventricular tachycardia and ventricular tachycardia/sudden cardiac death.
Researchers developed and validated a clinical and genetic score to identify individuals at high risk for atrial fibrillation and stroke.
The Axis, Burden, Coupling interval, Ventricular Tachycardia risk score was found to accurately predict adverse left ventricular remodeling as well as subsequent adverse events in patients with frequent premature ventricular contractions.
For patients with AF after PCI, dual therapy is associated with a reduced risk for bleeding compared with triple therapy.
The FDA has approved new dosing, monitoring, and evaluation recommendations for intravenous sotalol (Altathera), allowing for a reduction in hospital stay.
In patients hospitalized for COPD exacerbation, the presence of atrial fibrillation may increase the risk of in-hospital mortality.
An increased risk for incident atrial fibrillation was found to be associated with plasma levels of ceramides and sphingomyelins with palmitic acid.
Researchers evaluated whether certain electrocardiogram parameters reflecting ventricular repolarization may help in identifying scleroderma in patients with increased risk for ventricular arrhythmias.
Among hemodialysis patients with atrial fibrillation, racial/ethnic disparities in all-cause stroke are partially mediated by lower anticoagulant use.